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Abstract.  Rat vascular smooth muscle cells (SMC) in 
culture synthesize and  secrete a  ~38,000-Mr protein 
doublet or triplet that,  as previously described (Ma- 
jack and Bornstein.  1984. J.  Cell Biol.  99:1688- 
1695),  rapidly and reversibly accumulates in the SMC 
culture medium upon addition of heparin.  In the pres- 
ent study, we show that this '~38,000-Mr heparin- 
regulated protein is electrophoreticaUy and immu- 
nologically identical to apolipoprotein E  (apo-E), a 
major plasma apolipoprotein involved in cholesterol 
transport.  In addition,  we show that expression of apo- 
E by cultured SMC varies according to growth state: 
while proliferating SMC produced little apo-E and ex- 
pressed low levels of apo-E mRNA, quiescent SMC 
produced significantly more apo-E (relative to other 
proteins) and expressed markedly increased levels of 
apo-E mRNA.  Northern analysis of RNA extracted 
from aortic tissue revealed that fully differentiated, 
quiescent SMC contain significant quantities of apo-E 
mRNA. These data establish aortic SMC as a vascular 
source for apo-E and suggest new functional roles for 
this apolipoprotein, possibly unrelated to traditional 
concepts of lipid metabolism. 
HEROSCLEaOSlS is a complex disorder characterized 
by the  abnormal  proliferation  of vascular  smooth 
muscle cells (SMC) l and an altered  lipid  metabo- 
lism. Smooth muscle proliferation  in the vessel wall appears 
to be controlled by a balanced interplay of endogenous and/ 
or platelet-derived  mitogens  (38),  trophic or accessory fac- 
tors (such as lipoproteins;  12, 15, 19), and growth inhibitors 
(1,  5,  6,  8,  23).  Among the known growth  inhibitors  are 
heparin-like  glycosaminoglycans,  endogenous components 
of the vessel wall (32) that act as potent regulators  of SMC 
growth (5, 6, 7) and migration  (26). Heparin-like molecules 
appear to regulate SMC growth in late G1 (31) via a mecha- 
nism  involving  thrombospondin  (27-30),  an  extracellular 
matrix glycoprotein whose synthesis is regulated by platelet- 
derived growth factor (27, 30) but whose deposition into the 
matrix  is  inhibited  by heparin  (27). Investigations  of the 
effects of heparin on SMC function  have revealed a variety 
of phenotypic alterations  in heparin-treated  SMC (24,  25, 
27). In particular,  heparin-treated  SMC accumulate marked- 
ly increased  amounts  of a  ~38,000-Mr  protein  doublet in 
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the culture supernatant  (9, 24). The characteristics  of regula- 
tion of this protein by heparin have been fully described (24). 
In this study, we show that the "o38,000-Mr heparin-regu- 
lated protein is identical to apolipoprotein  E (apo-E), a major 
plasma apolipoprotein  that plays a central role in cholesterol 
homeostasis and serves as a ligand for the apo-B, E (LDL) 
receptor (20, 21). Using electrophoretic,  immunologic,  and 
Northern hybridization  techniques,  we establish  that aortic 
SMC synthesize and secrete apo-E and may therefore serve 
as an important  extrahepatic  source for this apolipoprotein. 
In addition,  we demonstrate that apo-E production varies ac- 
cording  to the proliferative  state of SMC in culture.  These 
data suggest an important  link between SMC proliferation 
and vessel wall lipid metabolism, both key elements  of the 
atherogenic  process. 
Materials and Methods 
Cell Culture 
Rat aortic SMC were grown from explants as described (27) and were sub- 
cultured  in  Waymouth's  medium  supplemented with  10%  FCS  (Gibco 
Laboratories, Grand Island, NY). Cells were used in the third to sixth pas- 
sage. Unless otherwise indicated, the following culture conditions were em- 
ployed. "Proliferative" SMC were prepared by plating cells at a density of 
1-5  x  104 cells/cm  2 and allowing them to proliferate for 24-48 h in 10% 
FCS. Growth factor-deficient (quiescent) SMC were prepared by maintain- 
ing similar cultures in 0.5% FCS for 72 h, or in 10% plasma-derived serum 
(PDS; HyCIone Laboratories, Logan, UT) for 96 h (27, 28). "Overconflu- 
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immunoisolation of apo-E from SMC culture medium. Prolifera- 
tive rat aortic SMC were metabolically labeled with [35S]methio- 
nine for 2 h (lanes I and 2) or 16 h (lanes 3-5). Heparin (100 Itg/ml) 
was added to the labeling medium at the time of metabolic labeling 
(lane 2 only). Culture medium was collected and either processed 
directly for SDS-PAGE (lanes 1-2) or treated with antiserum against 
rat plasma apo-E.  Antigen-antibody complexes were precipitated 
with protein A-Sepharose as described. Radiolabeled and immuno- 
isolated proteins were resolved on SDS-PAGE and visualized by au- 
toradiograpby. Shown are secretory profiles of proliferative SMC 
labeled in the absence (lane 1 ) or presence (lane 2) of heparin. Note 
the selective increase in a  'x,38,000-Mr  protein doublet (see refer- 
ence 26 for complete details). (Lanes 3-5) Immunoprecipitation  of 
SMC culture medium proteins with anti-apo-E antiserum. Lane 3, 
starting material (profile of secreted proteins before antibody treat- 
ment). Lane 4,  secreted proteins immunoisolated with apo-E an- 
tiserum.  (Note the specific precipitation of a  protein triplet with 
,,o37,000-39,000-M~  that  exactly  comigrates  with  the  heparin- 
inducible protein [lane 2].) Lane 5, secreted proteins precipitated 
by protein A-Sepharose alone (no antibody). A higher molecular 
mass  protein  (see  in  lane  4)  was  occasionally observed  to  be 
precipitated with one of our antibodies; its identity is not known. 
The positions of migration of molecular mass standards (xl0  -3) 
are shown to the left. 
ent, nonproliferative" cultures were obtained by allowing the cells to reach 
overconfluent (>2  x  l0  s cells/cm  2) densities in 10% FCS; growth curves 
revealed these cultures to be nonproliferative. 
Analytical Methods 
Metabolic labeling of cellular and secreted proteins was performed as de- 
scribed (24, 25, 27) by culturing cells for 2-16 h in serum-free medium lack- 
ing methionine in the presence of 50  I.tCi/ml  [~SS]methionine  (New En- 
gland Nuclear, Boston, MA). Labeled culture medium was harvested into 
protease inhibitors at 4°C to yield a final concentration of 25 mM EDTA, 
45  p.g/ml pepstatin,  1 mM N-ethylmaleimide, and 0.9 mM phenylmethyl- 
sulfonyl fluoride (PMSF).  Proteins were precipitated in  10%  TCA,  dis- 
solved in SDS-PAGE sample buffer (18),  and resolved on 8 or 10%  poly- 
acrylamide  gels.  All  samples  were  run  in  the  presence  of  50  mM 
dithiothreitol (DTT). Gels were fixed, dried, and exposed to film at -70°C. 
Radioactivity in autoradiographic bands was quantitated by optical density 
scanning using an Ephortec scanning densitometer (Joyce,  Loebl and Co. 
Ltd., Malden, MA). Underexposed films were analyzed to insure densito- 
metric readings in a  linear range. 
Immunoprecipitation from SMC culture medium was achieved by har- 
vesting radiolabeled conditioned medium into PBS containing 0.1%  SDS 
and 0.5% Triton X-10ft  Polyclonal antibodies against rat plasma apo-E or 
Figure 2. Effect of heparin on 
accumulation of the ~38,000- 
Mr  protein.  Proliferative  rat 
aortic SMC were metabolical- 
ly  labeled  with  [3SS]methio- 
nine for  2  h  in the  absence 
(lanes  1  and 2)  or  presence 
(lanes 3  and 4) of 100 gg of 
heparin/ml.  Culture medium 
proteins were  incubated with 
rabbit nonimmul~  serum (lanes 
I  and  3)  or  with  rabbit an- 
ti-rat plasma apo-E antiserum 
(lanes 2  and 4).  Immunoreactive proteins were precipitated with 
protein A-Sepharose and resolved on SDS-PAGE with subsequent 
autoradiography. Note that heparin treatment enhances extracellu- 
lar  accumulation of the  "o38,000-Mr  protein  recognized  by  the 
apo-E antibody. The positions of migration of molecular mass stan- 
dards (xl0  -3) are shown to the right. 
macrophage-derived apo-E, followed by protein A-Sepharose were used to 
specifically immunoisolate apo-E from the medium as described (16, 27). 
These antisera reacted only with apo-E when checked by immunoblotting 
against rat plasma apolipoproteins, lmmanoisolated proteins were resolved 
by one-dimensional SDS-PAGE  as described above, or by two-dimensional 
PAGE as described by O'Farrell (34) and modified by Skene and Shooter 
(40). Tube gels used were 1.5-mm-diam, containing 4% pH 3.5-10.0 and 
2% pH 4-6 ampholytes (34). 
Total RNA was prepared from SMC by the SDS-proteinase K method 
(39). RNA was prepared from  150-mm-diam plates of SMC grown and 
treated as described, or from SMC enzymatieally digested from the aortas 
of male Sprague-Dawley rats. The RNA samples (10 Itg per lane) were 
glyoxylated  before electrophoresis through an agarose gel formed in 10 mM 
phosphate, pH 6.8, then were electrophoretieally transferred to Genescreen 
Plus hybridization membranes (DuPont Co.,  Wilmington, DE; New En- 
gland Nuclear).  The  filters were UV cross-linked and prehybridized in 
0.5 M sodium phosphate (pH 7.2) containing 1 mM EDTA, 1% BSA, and 
7% SDS (7). DNA probes were then added (",,5 x  107 dpm/ml) and al- 
lowed to hybridize at 65°C for 12-20 h. Filters were washed in two changes 
of 0.1× SSC/I% SDS at 65°C, then were exposed to XAR-5 film (Eastman 
Kodak Co., Rochester, NY) with Cronex intensifying screens (DuPont Co.) 
at  -70°C. 
DNA probes were labeled with [32p]dCTP to a specific activity of 2-5 
x  10  s dpm/ng by random priming, using an oligo-labeling kit (Pharmacia 
Fine Chemicals, Piseataway, NJ) and following the instructions supplied by 
the manufacturer. The DNA probes used were 300-bp Pst I restriction frag- 
ments of pGR124, a cDNA encoding rat apolipoprotein E (33), and a 1.4-kb 
BamHI fragment of pPAI-I, a cDNA encoding human type I plasminogen 
activator inhibitor (a gift of Drs. L. Erickson and K. Marroti). The plas- 
minogen activator inhibitor probe recognized a single 2.3-kb transcript that 
is constitutively expressed by SMC in culture (30), and was used as a control 
for RNA loading and transfer. 
Results 
Rat aortic smooth muscle cells in culture synthesize and se- 
crete a  ,,,38,000-Mr protein doublet or triplet that accumu- 
lates in the culture supernatant in response to heparin treat- 
ment (Fig. 1). The selective increase in medium levels of this 
protein occurred without a concomitant change in total pro- 
tein synthesis (24, 25), and was independent of the effects of 
heparin on SMC growth (24).  SMC also synthesize and se- 
crete a  ~38,000-Mr protein doublet or triplet identified im- 
munologically as apo-E  (Fig.  1). 
We have investigated the relationship between the heparin- 
regulated ~38,000-Mr protein and apo-E, using immunologic 
and  electrophoretic  criteria.  Confluent,  nonproliferating 
SMC were metabolically labeled for 2  h  with  [35S]methio- 
nine in the presence  or absence of 100  Ixg of heparin/ml. 
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plasma apo-E, aortic SMC-derived apo-E, and 
macrophage-derived  apo-E.  Metabolically  la- 
beled SMC-derived apo-E was immunoisolat- 
ed  from SMC  culture  medium  as  described 
(see legend to Fig. 2). Before electrophoresis, 
unlabeled  rat plasma apo-E was added to the 
sample, and the resulting gel was stained with 
Coomassie Blue and photographed before auto- 
radiography.  Metabolically  labeled  macro- 
phage-derived  apo-E was prepared from su- 
pernatants  of a  glial  cell  culture  containing 
oligodendrocytes, astrocytes, and macrophages. 
Samples  were  subjected  to  two-dimensional 
PAGE as described in Materials and Methods. 
(a) Coomassie Blue-stained plasma apo-E. (b) 
Autoradiograph  of apo-E derived  from cul- 
tured  rat  aortic  SMC. (c) Autoradiograph  of 
apo-E  derived  from  cultured  macrophages. 
The slight difference in the electrophoretic pat- 
tern of  plasma apo-E (due to increased amounts 
of an isoforrn in the -l position with a molecu- 
lar mass similar to nonglycosylated apo-E) is 
commonly observed with isolated apo-E and is 
most likely related to deamidation during stor- 
age (44). The positions of  migration of  molecu- 
lar mass  standards  (xl0  -3) are shown to the 
right. 
Equal amounts of radioactively labeled culture medium were 
treated sequentially with anti-apo-E antiserum and protein 
A-Sepharose  and  the  precipitated  proteins  were  resolved 
by  SDS-PAGE.  As  shown  in  Fig.  2,  the  culture  medium 
from heparin-treated SMC contained large quantities of the 
~38,000-Mr  protein  precipitated  by  the  apo-E antiserum, 
whereas very little immunoprecipitable apo-E was identified 
in the culture supernatants of SMC labeled in the absence of 
heparin.  The identity of the  ,v38,000-Mr protein as apo-E 
was confirmed in these studies using two different apo-E an- 
tisera prepared against plasma apo-E, as well as with an anti- 
body prepared against macrophage apo-E. 
The  immunoisolated  ,'o38,000-Mr  protein  from the  cul- 
ture medium of heparin-treated SMC was compared to plas- 
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sional PAGE.  Plasma apo-E is composed of a  major band 
that represents the nonglycosylated form of the protein and 
variably sialylated forms that are more acidic and migrate 
with an increasing apparent molecular mass (producing the 
stairstep effect seen in Fig.  3 a;  37, 44).  As shown in Fig. 
3 b, the SMC-derived protein separated into three compo- 
nents with a pattern similar to that of plasma apo-E. In addi- 
tion, the pattern seen with apo-E derived from macrophages 
was very similar (Fig. 3 c). An increased degree of sialyla- 
tion of macrophage apo-E, as compared to plasma apo-E, 
has been previously reported (2, 43) and correlates with the 
increased amounts of the apparently higher molecular mass, 
acidic forms immunoprecipitated from the SMC and macro- 
phage culture media. No radiolabeled proteins correspond- 
ing to apo-E could be precipitated from SMC culture medi- 
um treated with nonimmune serum (data not shown). On the 
basis  of these data,  we concluded that the SMC-derived, 
heparin-inducible ~38,000-Mr protein was apo-E. 
As shown in our previous studies (24) and in Table I, addi- 
tion of heparin to SMC cultures results in a rapid accumula- 
tion of apo-E in the SMC culture medium.  We have used 
Northern  blot  analysis  to  estimate  the  amount  of apo-E 
mRNA in control and heparin-treated SMC, to determine if 
the increase in extracellular apo-E content was accompanied 
by a  concomitant increase in apo-E transcripts.  RNA was 
prepared from overconfluent, nonproliferative cells in  the 
absence or presence of heparin (100 I~g/ml for 72 h). As in 
our previous studies (24), these nonproliferative conditions 
were selected in an attempt to dissociate the direct effects of 
heparin from other effects secondary to SMC growth inhibi- 
tion. As shown in Fig. 4, heparin treatment did not result in 
an increase in apo-E mRNA  levels under nonproliferative 
conditions, despite a marked accumulation of secreted apo-E 
in the heparin-treated cultures (24). These data suggest that 
heparin exerts a posttranscriptional or postsecretional effect 
on apo-E accumulation in the medium. However, when RNA 
was prepared from sparse proliferating cells and from sparse 
cells growth-inhibited by heparin, a marked increase in apo- 
E  message levels was observed in the heparin-treated cul- 
tures (Fig. 4). Thus apo-E mRNA levels appear to increase 
as a function of growth inhibition rather than heparin treat- 
ment. On the basis of these and previous (24) data, we con- 
clude that the effects of heparin on apo-E production may 
occur at two levels: directly,, via a posttranscriptional or post- 
secretional effect, and indirectly, via the establishment of a 
quiescent state. 
We next examined the role of quiescence in determining 
apo-E expression by SMC,  using  metabolic labeling tech- 
niques.  SMC were made quiescent by maintaining the cul- 
Table L Accumulation of Secreted Apo-E by Vascular SMC 
as a Function of Quiescence or Heparin Treatment 
Apo-E 
(in relative  levels)* 
Control (10% FCS) 
+  heparin (100 ~tg/ml; 2 h) 
Quiescent (10% PDS; 96 h) 
Quiescent (0.5% FCS; 72 h) 
Quiescent (0.5% FCS) +  heparin 
1.8 5= 0.6 
20.3 5- 3.2 
6.8  + 2.6 
8.6 5-  1.5 
25.5 + 3.0 
* Expressed as a percent  of total secreted  radioactivity  as determined  by scan- 
ning densitometry  of SDS-PAGE  autoradiographs. 
tures in 0.5% FCS for 72 h or in 10% PDS for 96 h (27, 28). 
The nuclear labeling indices (over a  30-h period) of SMC 
maintained under these conditions was found to be <10% 
(29). As shown in Fig. 5, the apo-E content of  the media from 
quiescent SMC was markedly higher than that from prolifer- 
ative cells at the same cell density. Addition of heparin fur- 
ther increased the accumulation of newly synthesized apo-E 
in the quiescent cells (Fig. 5).  Scanning densitometry was 
used to quantitate the relative levels of apo-E secreted by 
SMC under various culture conditions (Table I). Cells ren- 
dered quiescent in 0.5 % FCS or 10% PDS produced an aver- 
age of four- to  fivefold more apo-E (as a  percent of total 
secreted protein) than did proliferative cells. The addition of 
heparin to proliferating SMC resulted in a  10-fold increase 
of accumulated apo-E in the culture supernatant.  Note that 
this increase is very rapid and occurs within 2 h (Table I and 
reference 24),  well  before the  antiproliferative effects of 
heparin become apparent.  Heparin treatment of quiescent 
SMC elicited a similar increase in extracellular apo-E levels 
(Table I). 
To determine if the enhanced production of apo-E by quies- 
cent SMC correlated with an increase in apo-E mRNA lev- 
els,  we compared RNA  prepared from proliferative SMC 
with  RNA  prepared from SMC  growth  arrested  in  0.5% 
Figure 4.  Northern  analysis of RNA prepared from control and 
heparin-treated SMC under proliferative  and nonproliferative  (over- 
confluent) conditions. Total RNA was prepared from overconflu- 
ent, nonproliferating SMC cultures (lane 1), overconfluent, non- 
proliferating SMC treated for 72 h with 100 ~tg of heparin/ml (lane 
2),  sparse, proliferating SMC (lane 3), and sparse proliferating 
SMC after growth arrest with heparin for 72 h (lane 4).  These 
RNAs (10 I.tg/lane) were subjected to Northern analysis with 32p_ 
labeled rat apo-E cDNA probe. The apo-E cDNA recognizes a sin- 
gle SMC mRNA species at 1.2 kb. Note that heparin has no direct 
effect on apo-E message levels in nonproliferative cultures under 
conditions in which extracellular apo-E levels are greatly induced 
(24). Apo-E mRNA content  is  markedly  induced,  however, in 
sparse SMC growth-arrested by heparin. Bars (left) indicate the po- 
sitions of migration of 28S and  18S ribosomes. 
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tion of growth state and heparin  treatment.  Se- 
creted SMC proteins were metabolically labeled as 
described, resolved on SDS-PAGE, and visualized 
by autoradiography. Shown are secretory pheno- 
types of SMC proliferating in 10% FCS (lane 1), 
proliferating SMC treated with heparin  for 2 h 
(lane 2),  and SMC  rendered quiescent in 0.5% 
FCS for 72 h (lane 3). (Lanes 4 and 5) Secretory 
phenotypes of 0.5% FCS-arrested SMC labeled 
for 2 h in the absence (lane 4) or presence (lane 
5)  of heparin.  Enhanced production  of throm- 
bospondin (TS) and a secreted "~55,000-Mr pro- 
tein (sp 55) serve as markers for growth stimula- 
tion by FCS (lanes I and 2). Medium TS levels are 
also increased in heparin-treated cells (lanes 2 and 
5; see reference 27 for details). Bracket indicates 
the position of migration of apo-E in the two exam- 
ples  shown here.  Note enhanced  expression of 
apo-E in heparin-treated and growth-arrested  cells. 
The positions of migration of molecular mass stan- 
dards (xl0  -3) are shown to the left. 
FCS. As shown in Fig. 6, quiescent SMC in culture contain 
significantly elevated amounts of apo-E mRNA as compared 
to proliferating controls. These data are consistent with the 
data derived from the metabolic labeling experiments de- 
scribed above, which demonstrated markedly increased pro- 
duction of apo-E by quiescent cells. The data presented in 
Fig. 6 are derived from cells growth arrested in 0.5 % FCS 
for 72 h;  a  similar increase in apo-E mRNA was also ob- 
served in cells made quiescent in  10%  PDS (not shown). 
SMC isolated directly from normal aortic tissue also con- 
tained substantial levels of apo-E message (Fig. 6), suggest- 
ing that apo-E production is a normal differentiated function 
of quiescent SMC in vivo. 
Discussion 
Apo-E is the protein moiety of several classes of plasma lipo- 
proteins and serves as the ligand responsible for mediating 
their binding to the apo B,E (LDL) receptor (for reviews see 
references 20 and 21). Apo-E is synthesized by a variety of 
cell types, including macrophages and astrocytes (3, 4,  10, 
11,  20),  and  may function in cholesterol transport among 
various cells in the body, especially during tissue growth or 
repair  (14,  17). For example,  high levels of macrophage- 
derived apo-E have recently been shown to accumulate in in- 
jured peripheral nerves during periods of degeneration and 
regeneration (16, 42; Boyles, J. K., D. Y. Hui, K. H. Weis- 
graber, R. E. Pitas, and R. W. Mahley, unpublished data); 
this apo-E is believed to participate in the redistribution of 
cholesterol derived from degenerating myelin (Boyles, J. K., 
D. Y. Hui, K. H. Weisgraber, R. E. Pitas, and R. W. Mahley, 
unpublished data). Other (nonlipid transport) roles for apo-E 
in tissue injury and repair have not, however, been excluded. 
In this  study we demonstrate that rat aortic SMC express 
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and quiescent cultures, and from SMC isolated from an in vivo 
source. Total  RNA was prepared from sparsely plated proliferative 
SMC (lane 1 ), sparse SMC growth-arrested by serum deprivation 
(72 h in 0.5% FCS (lane 2), and SMC enzymatically  released from 
the abdominal aortas of 4-mo-old male rats (lane 3). These RNAs 
(10  gg/iane)  were subjected to  Northern  analysis with  a  32p_ 
labeled rat apo-E cDNA probe. Cells growth arrested by culture in 
low (0.5 %) serum for 72 h (lane 2) exhibit markedly increased lev- 
els of apo-E mRNA. SMC isolated from aortic tissue in vivo also 
express a significant  amount of apo-E message. Bars (le~) indicate 
the positions of migration of 28S and 18S ribosomes. 
apo-E mRNA and, in culture, synthesize and secrete a pro- 
tein with electrophoretic and immunologic identity to plasma 
and macrophage-derived apo-E.  In addition, we establish 
identity of apo-E with a previously described •38,000-Mr 
protein that accumulates in the SMC culture medium in re- 
sponse to heparin (25),  and show that apo-E expression is 
enhanced during SMC quiescence. 
A  recent paper by Driscoll and Getz (10) demonstrated 
that SMC cultured from monkey aorta synthesize and secrete 
a protein recognized by an antibody against plasma apo-E. 
Using  rat aortic  SMC,  we have rigorously proven  (using 
three apo-E antisera, two-dimensional PAGE analysis, and 
Northern hybridization techniques) that SMC in culture pro- 
duce apo-E. In addition, we show that aortic SMC in vivo 
contain significant  amounts  of apo-E mRNA. Our data clear- 
ly establish SMC as an additional extrahepatic source for 
apo-E. Production of this apolipoprotein directly by vascular 
tissues may be of  particular relevance to the atherogenic pro- 
cess, which is characterized by cellular proliferation (requir- 
ing de novo membrane synthesis) and an abnormal lipid me- 
tabolism. 
Heparin-like molecules are endogenous components of the 
vessel wall (32) that probably exist in the extracellular matrix 
in the form of heparan sulfate proteoglycans. Current the- 
ories emphasize the "protective" role that these molecules 
may serve in prohibiting or controlling SMC proliferation in 
vivo after vascular injury or trauma (6). In culture, SMC ex- 
posed to heparin accumulate large amounts of the '~38,000- 
Mr protein  (9,  24)  identified herein as apo-E.  Heparin  is 
known to bind apo-E (22, 42) and can prevent the interaction 
of apo-E-containing lipoproteins with the apo-B,E (LDL) 
receptor (13). It is likely that heparin contributes to the ac- 
cumulation of apo-E in SMC cultures by a postsecretional 
mechanism, either by inhibiting the receptor-mediated up- 
take of secreted apo-E or by binding to the apo-E and pre- 
venting its extracellular degradation. This hypothesis is sup- 
ported by the very rapid kinetics of induction after addition 
of heparin to the SMC culture medium (24), the immediate 
reversal of the effect upon removal of heparin (24), and the 
absence  of detectable change in apo-E  mRNA after pro- 
longed heparin treatment of confluent cells  (Fig.  4).  If a 
similar phenomenon occurs in vivo, the presence of endoge- 
nous extracellular heparans may serve an important regula- 
tory function in vascular lipid metabolism. 
In addition to these probable postsecretional effects, hepa- 
rin treatment appears to exert an indirect effect on the expres- 
sion of apo-E via the induction of cellular quiescence. We 
have found that sparse SMC growth arrested by heparin ex- 
hibit increased apo-E mRNA in the absence of a direct effect 
of heparin on apo-E message levels under nonproliferative 
(overconfluent) culture conditions. Expression of apo-E by 
cultured SMC therefore appears to be controlled, at least in 
part, by growth state.  In support of this hypothesis, we have 
shown that SMC maintained in low (0.5%) or plasma-de- 
rived serum (which lacks platelet products) secrete increased 
amounts of apo-E. The increased production of apo-E was 
accompanied by a concomitant increase in apo-E mRNA lev- 
els, and correlated with the establishment of a quiescent state 
due to growth factor deprivation.  These observations,  to- 
gether with our demonstration of significant levels of apo-E 
mRNA in aortic tissue in vivo, may relate to the findings of 
Owens et al. (35, 36), who suggest that growth arrest (by se- 
rum deprivation) promotes the cytodifferentiation  of cultured 
SMC. Our data clearly establish that apo-E gene expression 
is a constitutive function of fully differentiated SMC, and 
that expression of this differentiated function is enhanced by 
quiescence in culture.  More importantly, the data suggest 
that stimulation of SMC proliferation in vivo (e.g., after vas- 
cular injury) may lead to profound alterations in vessel wall 
lipid metabolism. 
In summary, we have shown that aortic SMC synthesize 
and secrete apo-E, and that apo-E is the previously studied 
,'o38,000-Mr protein regulated by heparin in SMC cultures 
(9, 24). The mechanism underlying the increased accumula- 
tion of secreted apo-E in heparin-treated, nonproliferating 
(overconfluent) cultures was not examined but most probably 
occurs at a postsecretory level. We have also shown that cells 
maintained in low or plasma-derived serum secrete tbur- to 
fivefold more apo-E than do proliferating cells. The increased 
apo-E production occurred concomitant with growth arrest 
and was associated with a marked increase in apo-E mRNA. 
Heparin-mediated inhibition of SMC growth also resulted in 
increased apo-E message levels. Taken together, the available 
data suggest intriguing relationships among apo-E, endoge- 
nous vessel wall heparans, and SMC growth and/or differ- 
entiation. Further studies on the functional role of apo-E in 
SMC biology, on the functional consequences of interactions 
between heparin and apo-E, and on relationship(s) among 
SMC  proliferation,  apo-E  gene expression,  and  vascular 
lipid metabolism are clearly indicated. 
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